Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRT plus CAPOX versus SCRT plus CAPOXIRI for locally advanced rectal cancer
jRCTs031220342Phase 3Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin and irinotecan in rectal cancer (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Organ preservation adapted disease free survival. Started Nov 2022; status: recruiting.
02
Drugs
capecitabineoxaliplatinirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs031220342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220342.